Novocure Posts Data For Tumor Treating Fields In Brain Tumor Trial

  • Novocure Ltd NVCR has released updated data from the Phase 2 pilot 2-THE-TOP of Tumor Treating Fields (TTFields) together with pembrolizumab and temozolomide for newly diagnosed glioblastoma (GBM). 
  • Of the 19 patients with follow-up over nine months, the median progression-free survival was at least 11.2 months compared to 6.7 months from the historical control study (EF-14), in which patients received TTFields and adjuvant temozolomide. 
  • Twelve (48%) were progression-free, and 15 (60%) were still alive. Six (24%) patients with measurable tumors achieved partial or complete response. 
  • The most common adverse events were thrombosis (4 patients, 16%), seizure (3 patients, 12%), and metabolic disturbances (2 patients, 8%).
  • Related Link: Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer.
  • Price Action: NVCR shares are down 1.96% at $112.81 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralbrain cancerBrain TumorBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!